Impact of All‐Oral Direct‐Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States

Approved treatment for hepatitis C virus (HCV) with all‐oral direct‐acting antivirals (DAA) therapy is now entering into its fourth year; however, little has been reported on the real‐world clinical (decompensated cirrhosis [DCC] and hepatocellular carcinoma [HCC]) and economic outcomes. A retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Haesuk, Wang, Wei, Henry, Linda, Nelson, David R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393174/
https://www.ncbi.nlm.nih.gov/pubmed/30289989
http://dx.doi.org/10.1002/hep.30303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393174/
https://www.ncbi.nlm.nih.gov/pubmed/30289989
http://dx.doi.org/10.1002/hep.30303

Ejemplares similares